Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374120 · ClinicalTrials.gov registry record
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,480
- Enrollment target
NCT07374120 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,480 participants.
The verdict
NCT07374120 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,480 participants
- Enrollment target
Study Summary
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,480 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2025-01-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07374120
The ClinicalTrials.gov registry entry for NCT07374120 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07374120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07374120 about?
NCT07374120 is a clinical study titled "Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting". This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Pati...
What is the current status of trial NCT07374120?
This trial is currently completed. The enrollment target is 1,480 participants. The study started on 2024-02-01. Estimated completion is 2025-01-21.
Who is sponsoring clinical trial NCT07374120?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.